Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Jersey Health Reporter.
Press releases published on August 14, 2025
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Home Use
GlobeNewswire
·
August 14, 2025
10-minute home test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancer H. pylori linked to approximately 80% of gastric cancer cases; classified as a Class 1 carcinogen by the World Health Organization …
Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins
GlobeNewswire
·
August 14, 2025
REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art …
Polyrizon Regains Compliance with Nasdaq Listing Requirements
GlobeNewswire
·
August 14, 2025
Ra’anana, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced that it has received formal confirmation from the …
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
GlobeNewswire
·
August 14, 2025
SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“ …
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update
GlobeNewswire
·
August 14, 2025
First commercial sales of LYTENAVA™ (bevacizumab gamma) achieved in Europe ONS-5010/LYTENAVA™ (bevacizumab-vikg) Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, in the United States ISELIN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- …
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
August 14, 2025
Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during an oral presentation at the 2025 Annual Meeting of the American Society of Clinical …
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025
GlobeNewswire
·
August 14, 2025
DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings (Nasdaq: LIXT), a clinical-stage …
BCC Research Forecasts Steady 4.6% CAGR for Blood Platelet Market Through 2030
GlobeNewswire
·
August 14, 2025
Boston, Aug. 14, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the “Global Blood Platelet Market” is expected to grow from $3.2 billion in 2025 to $4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 4.6% …
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
GlobeNewswire
·
August 14, 2025
Company and Former Cincinnati Bengals Running Back Known for the “Ickey Shuffle” Collaborate to Raise Awareness and Drive Asthma Education with Focus on Acute Attacks SAN DIEGO and CINCINNATI, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings …
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
GlobeNewswire
·
August 14, 2025
NORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and six months …
Global Pulse Oximeters Market Set to Surpass USD 7.03 Billion by 2032 | MarketsandMarkets™
GlobeNewswire
·
August 14, 2025
Delray Beach, FL, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Advanced patient monitoring solutions see rising adoption amid aging populations, chronic disease prevalence, and healthcare infrastructure expansion The global pulse oximeters market, valued at US$3.59 …
Stryker to participate in the 2025 Wells Fargo Securities Healthcare Conference
GlobeNewswire
·
August 14, 2025
Portage, Michigan, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2025 Wells Fargo Securities Healthcare Conference on Thursday, September 4, at the Encore Boston Harbor. Andy Pierce, Group President, MedSurg and …
Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability
GlobeNewswire
·
August 14, 2025
WESTBROOK, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health and wellness company, is announcing its financial results for the three months ended June 30, 2025. “We are pleased to …
Halda Therapeutics Receives FDA Fast Track Designation for HLD-0915 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
GlobeNewswire
·
August 14, 2025
NEW HAVEN, Conn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of therapies called RIPTAC™ Therapeutics, today announced that the U.S. Food and Drug Administration (FDA) granted Fast …
Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
GlobeNewswire
·
August 14, 2025
Favorable CDI-988 Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later this year BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or …
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
GlobeNewswire
·
August 14, 2025
Echocardiographic data analysis demonstrated favorable impact of atrioventricular interval modulation (“AVIM”) therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of heart failure with preserved ejection …
Analytics For Life Completes Clinical Study of Non-Invasive Point-of-Care Test for Elevated Pulmonary Capillary Wedge Pressure (PCWP) Using Machine Learning
GlobeNewswire
·
August 14, 2025
Study achieves primary sensitivity endpoint, advancing diagnostics for heart failure with preserved ejection fraction (HFpEF) and pulmonary hypertension (PH) Results build on data previously presented at ACC.25 in March 2025 TORONTO and BETHESDA, Md., Aug. …
VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
GlobeNewswire
·
August 14, 2025
BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune- …
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 14, 2025
—Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase 2 SPRING Trial Data Highlighting Nebokitug’s Unique Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects …
Lifeward Ltd. Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 14, 2025
Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process Appoints new CEO and CFO to spearhead strategic …